NDA, BLA Submissions Expected To Fall Again in FY 2011
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA estimates that the number of fee-paying applications will continue to decline, meaning the user fee itself will increase more than 19% to $1.842 million for applications requiring clinical data.
You may also be interested in...
FDA Sees Another Submission Decrease In FY 2011, Increases Application Fees
The figures continue a recent trend of decreases in fee-paying full application equivalents but were not as low as had been estimated.
FDA Sees Another Submission Decrease In FY 2011, Increases Application Fees
The figures continue a recent trend of decreases in fee-paying full application equivalents but were not as low as had been estimated.
User Fee Triggers Require Care In Unfriendly Budget Environment, Ventimiglia Says
Trigger changes could feed argument that user fees are a tax on industry.